---
title: "DUALITYBIO's core product DB-1303/BNT323 listing application has been accepted"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282224696.md"
description: "DualityBio announced that its new drug application for the core product DB-1303/BNT323 has been accepted by the National Medical Products Administration. This application is based on positive results from a Phase III pivotal clinical study aimed at evaluating the efficacy and safety of DB-1303 in patients with HER2-positive unresectable or metastatic breast cancer"
datetime: "2026-04-09T15:56:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282224696.md)
  - [en](https://longbridge.com/en/news/282224696.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282224696.md)
---

# DUALITYBIO's core product DB-1303/BNT323 listing application has been accepted

DualityBio-B (09606.HK) announced that the company's core products DB-1303/BNT323 have received positive results from the pivotal Phase III clinical study, and based on the feedback from the communication with the Center for Drug Evaluation of the National Medical Products Administration regarding the new drug application, the submitted new drug application for the biological product has been accepted by the National Medical Products Administration.

The Phase III clinical trial aims to evaluate the efficacy and safety of DB-1303 compared to T-DM1 in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and taxane treatment

### Related Stocks

- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [BNTX.US](https://longbridge.com/en/quote/BNTX.US.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [09606.HK](https://longbridge.com/en/quote/09606.HK.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)

## Related News & Research

- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Fingerprint Cards AB Bets on Merger-Led Turnaround](https://longbridge.com/en/news/286333864.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [01:00 ETNational Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation](https://longbridge.com/en/news/286359416.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)